"
Team:BrownTwo/Limiter/utility
From 2008.igem.org
(Difference between revisions)
| (12 intermediate revisions not shown) | |||
| Line 5: | Line 5: | ||
<p>Much as excessive signal levels can destroy a radio transmitter, excessive genetic expression can cause damage in living systems. While cells are usually well-equipped to modulate their own transcriptional behavior, an investigation into pathological gene expression indicates that many situations arise wherein the expected regulatory response fails. Our device is designed to augment endogenous gene regulatory pathways.</p> | <p>Much as excessive signal levels can destroy a radio transmitter, excessive genetic expression can cause damage in living systems. While cells are usually well-equipped to modulate their own transcriptional behavior, an investigation into pathological gene expression indicates that many situations arise wherein the expected regulatory response fails. Our device is designed to augment endogenous gene regulatory pathways.</p> | ||
| - | <p>While one can surely identify numerous cases of abnormal gene expression in cellular systems, we turn our attention to one particular network related to a crucial decision in cell fate, apoptosis.</p> | + | <!-- |
| - | + | <p>While one can surely identify numerous cases of abnormal gene expression in cellular systems, we turn our attention to one particular network related to a crucial decision in cell fate, apoptosis.</p> | |
=Cellular suicide and the cancer phenotype= | =Cellular suicide and the cancer phenotype= | ||
| Line 25: | Line 25: | ||
In designing a system to target abnormally-absent apoptosis, one can consider two approaches. It is possible to identify a key anti-apoptotic factor that requires down-regulation or, conversely, to target a pro-apoptotic factor that requires up-regulation. For the former, one might consider X-linked Inhibitor of Apoptosis (XIAP), which, while not present on the above figure, is responsible for inhibiting caspases (Vucic and Fairbrother, 2007). Caspase activation in the apoptotic pathway can be considered to be a point of no return, a trigger for the irreversible decision to undergo cellular suicide. Downregulation of XIAP should thus help initiate apoptosis. Alternatively, mutations in the gene encoding p53 have been found to exist in 50% of cancers (Toledo and Wahl, 2006). These mutations occur overwhelmingly in the DNA binding domain of this protein, thus disabling its ability as a transcriptional regulator. Since the inhibition of apoptosis stems from a defective p53, it might be necessary to introduce a protein into the cell with analogous activity to p53. Upregulation of this exogenous genetic input would then result in apoptosis. | In designing a system to target abnormally-absent apoptosis, one can consider two approaches. It is possible to identify a key anti-apoptotic factor that requires down-regulation or, conversely, to target a pro-apoptotic factor that requires up-regulation. For the former, one might consider X-linked Inhibitor of Apoptosis (XIAP), which, while not present on the above figure, is responsible for inhibiting caspases (Vucic and Fairbrother, 2007). Caspase activation in the apoptotic pathway can be considered to be a point of no return, a trigger for the irreversible decision to undergo cellular suicide. Downregulation of XIAP should thus help initiate apoptosis. Alternatively, mutations in the gene encoding p53 have been found to exist in 50% of cancers (Toledo and Wahl, 2006). These mutations occur overwhelmingly in the DNA binding domain of this protein, thus disabling its ability as a transcriptional regulator. Since the inhibition of apoptosis stems from a defective p53, it might be necessary to introduce a protein into the cell with analogous activity to p53. Upregulation of this exogenous genetic input would then result in apoptosis. | ||
| - | In either situation, | + | In either situation, it is essential to keep in mind that the maintenance of factors that promote and inhibit apoptosis defines a healthy cell. Any regulatory system set in place must respond appropriately to apoptotic stimuli, and should otherwise exist passively in the system when no regulation is needed. These considerations emphasize the need for a limiter-type regulatory device. |
=Apoptosis in yeast= | =Apoptosis in yeast= | ||
| - | While still an ongoing debate, there is increasingly more evidence that yeast | + | While still an ongoing debate, there is increasingly more evidence to suggest that yeast have apoptosis as well (Frohlich et al., 2007). Despite the fact that apoptosis seems to make most sense in a multicellular context, the organisms nonetheless show signs characteristic of a programmed cell death. In fact, much research about apoptotic pathways from mammals can be conducted in yeast, due to the fact that many of the genes and pathways present in mammals share homology to those found in yeast. Given this promising range of homology, one might consider first applying the regulatory approach discussed above for mammals in a yeast framework. A limiter device in yeast could also serve as a useful tool for understanding important nodes in the apoptotic network. |
| - | + | ||
| - | + | ||
| - | + | ||
=References= | =References= | ||
| + | <br>1. Frohlich et al. Yeast apoptosis—From genes to pathways. ''Seminars in Cancer Biology'' 17 (2007) 112–121 | ||
| + | <br>2. Toledo and Wahl, Regulating the p53 pathway:in vitro hypotheses, in vivo veritas, ''Nature Reviews'' vol 6. 2006 | ||
| + | <br>3. Vucic and Fairbrother, The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer, ''Clin Cancer Res.'' 2007;13(20) | ||
| - | + | --!> | |
| - | + | ||
| - | + | ||
Latest revision as of 16:34, 8 November 2010
The utility of threshold limitationMuch as excessive signal levels can destroy a radio transmitter, excessive genetic expression can cause damage in living systems. While cells are usually well-equipped to modulate their own transcriptional behavior, an investigation into pathological gene expression indicates that many situations arise wherein the expected regulatory response fails. Our device is designed to augment endogenous gene regulatory pathways.
|
